We are adding THRX (NASDAQ) pending FDA PDUFA Telavancin on 9/16/09

TICKER            BUY AREA     QUOTE NOW      POSITION           DRIVER

THRX (NASDAQ) MARKET OPEN                 SHORT TERM   FDA PDUFA Telavancin on 9/16/09
VVUS (NASDAQ)USD 6,9 USD      6,9                LT         STRONG CONSENSUS
HGSI (NASDAQ) USD 14,42        15                  LT      LUPUS DRUG SUCCESSFUL
ARNA (NASDAQ) USD 5,05       5,05       SHORT TERM PENDING SEPTEMBER CLINICAL DATA
SQNM (NASDAQ) USD 5,85    6,35(+8%) SOLD 
TSPT (NASDAQ) USD 7,8          8,1              LT  INTERMEZZO PENDING FDA APPROVAL-PARTNERSHIP
ALXA (NASDAQ) USD 2,28         2,6             LT                 STRONG CONSENSUS
CYTK (NASDAQ) USD 3             3,1            LT      STRONG CONSENSUS PENDING CLINICAL DATA
ARIA (NASDAQ) USD 2,35    1,90 SOLD (-19%)
AEZS(NASDAQ) USD 2,1        2,55             LT   STRONG CONSENSUS, PENDING DATA
JAV (AMEX)   USD 1,3          1,9               LT              STRONG CONSENSUS
NPSP (NASDAQ) USD 4,7     4,1               LT              STRONG CONSENSUS
ONXX(NASDAQ) USD 35,9   31,2              LT                     OVERSOLD
IDIX (NASDAQ) USD 4,44        4,2 SOLD(-5%)
SNTS (NASDAQ) USD 2,81    3,25 SOLD(+17%)
BFRM (NASDAQ) USD 2,85   2,6        LONG TERM
OCLS (NASDAQ) USD 2,85    2,45 SOLD (-15%)
TRGT (NASDAQ) USD 5,5     8,7 SOLD(+60%)
OREX (NASDAQ) USD 5,35    6,45 SOLD(+20%)
FOLD (NASADQ) USD 10    10,4        LONG TERM       PLICERA, AMIGAL, STRONG CONSENSUS
SOMX (NASDAQ) USD 1,10  1,38 SOLD (+25%)
DDSS (NASDAQ) USD 2,65   1,95        HOLD                            TRAZODONE 
XNPT (NASDAQ) USD 21,85  21,4     LONG TERM            XP19986 POSITIVE TRIAL 6/30/09
VNDA (NASDAQ) USD12,1    15,2 SOLD (+25%)
CYTR (NASDAQ) USD 1,02    1,05     LONG TERM                 STRONG CONSENSUS
JAZZ (NASDAQ) USD 4,95   7,3 SOLD (+45%)
PARD (NASDAQ) USD 5    5,9 PROFIT TAKING(+18%)
PARD (NASDAQ) USD 6,6  rebought 7/2 7,2 SOLD (+9%)
INCY (NASDAQ) USD 3,5      5,2    SOLD (+50%)
ISTA (NASDAQ) USD 4,1   5,15         LONG TERM               BEPREVE FDA PDUFA 9/12/09
SLXP (NASDAQ) USD 9,9   12,5         LONG TERM      STRONG CONSENSUS FDA PDUFA 9/9/09
MAPP (NASDAQ) USD 11,3  10    REBUYING LONG TERM        STRONG CONSENSUS
ARYX (NASDAQ) USD 4,5    SOLD 2,5 (-45%)
ARRY (NASDAQ) USD 3,1    4,2 SOLD (+30%)
GTXI (NASDAQ) USD 9,5  10         LONG TERM FDA                   PDUFA 10/30/09
UTHR (NASDAQ) USD 84    96 SOLD (+15%)
NGSX (NASDAQ) USD 6,4    8,2 SOLD(+30%)
VICL (NASDAQ) USD 3      3,7          LONG TERM                            SWINE FLU
STAA (NASDAQ) USD 3,3 2,62         LONG TERM               FDA CLEARENCE FOR Epiphany(TM)
ALTH (NASDAQ) 7,9      8,1             LONG TERM                    FDA PDUFA 9/24/09
AMAG (NASDAQ) 52,8   45,2           LONG TERM           FDA APPROVES FERAHEME 6/30/09
XOMA (NASDAQ) 1,2    0,92            LONG TERM                            OVERSOLD
HEB (AMEX) 3,3(5%OF CAPITAL) 2,25 SOLD(-35%)
HEB (AMEX) was rebought after 100% gain (see old posts)
MRNA (NASDAQ) 3,3           1,4 SOLD (-55%)
RIGL (NASDAQ) USD 10        10,1 SOLD FLAT
MITI (NASDAQ) USD 6   6,15              LONG TERM                           OVERSOLD
MNKD (NASDAQ) USD 8,3     7,95 SOLD(-4%)
SVNT (NASDAQ) USD 7,10     13 SOLD(+90%)
NPSP (NASDAQ) 3,1 USD      4,75 SOLD(+50%)
SCLN (NASDAQ) 2,25 USD      2,7 SOLD (+20%) 
MAPP (NASDAQ) 8 USD (posts from 5/26) PROFIT TAKED(+45%) LEVADEX
VNDA (NASDAQ) 8 USD (see old post 5/8) PROFIT TAKED(+80%) FANAT
CLDA (NASDAQ) 15,7 USD 14,5           LONG TERM
CTIC (NASDAQ) 2,10 USD    1,39 SOLD (-35%)
ANPI (NASDAQ) 2 USD         1,39 SOLD(-30%)
MEDX (NASDAQ) 7,5 USD     8,7 PROFIT TAKING(+20%)
MNTA (NASDAQ) 8,9 USD  11             LONG TERM                   STRONG CONSENSUS
ACAD (NASDAQ) 2,6 USD      5 SOLD (+95%)
ACOR (NASDAQ) 24 USD        23,5 SOLD (-2%) FAMPRIDINE-SR, FDA PDUFA 10/22/09
BDSI (NASDAQ) USD 5,45    PROFIT TAKED 6,3 (+18%)
BDSI (NASDAQ) 6,6  rebought at 5,4      SHORT TERM         ONSOLIS APPROVED BY FDA
DNDN (NASDAQ) 22 USD (see old post 4/27) 24,1 LONG TERM             PROVENGE
SPPI (NASDAQ) 4 USD    (see ols post 5/12) 6/12 PROFIT TAKING (+35%)
SPPI (NASDAQ) 5,85 USD          7,4 PROFIT TAKING(+28%)
SPPI (NASDAQ) 6,5 USD rebought 7/2 7,1 LT ZEVALIN FDA PDUFA 09/07/09 FUSILEV PDUFA 08/10/09